Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 04/02/15

Translational Science Laboratory at
the Frederick National Laboratories
for Cancer Research

The Translational Science Laboratory contributes broadly to collaborative projects. For example, detailed cell-based studies including experiments with endothelial cells to assess antiangiogenic potential, cancer cell and normal cells to assess potential for therapeutic benefit that contribute to the evaluation of varied natural product and synthetic compounds are performed regularly.1-6 In collaboration with the in vivo group, more than 2000 xenograft tissues collected have been processed by snap-freezing, formalin-fixing and isolation of RNA and DNA in a study which will provide a great resource to the cancer research community. The final database will allow comparison of gene expression for the same cell lines grown in culture and as xenografts over the course of several passages.

The role of this lab is to be flexible and contribute to multiple projects within the branch and in collaboration with NExT projects, other branches and the cancer research community.

References

  1. Jobson AG, Lountos GT, Lorenzi PL, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH, Pommier Y. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of campothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Therap 2009; 331: 816-26.
  2. Monks A, Hose C, Pezzoli P, Kondapaka S, Vasant G, Petersen KD, Sehested M, Monteforte J, Shoemaker RH. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with corresponding signature in xenografts. Anticancer Drugs 2009; 20: 682-92.
  3. Galal AM, Gul W, Slade D, Ross SA, Feng S, Hollingshead MG, Alley MC, Kaur G, ElSohly MA. Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity. Bioorg Med Chem 2009; 17: 741-51.
  4. Kaur G, Hollingshead M, Holbeck S, Schauer-Vukasinovic V, Camalier RF, Domling A, Agarwal S. Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic nautral product. Biochem J 2006; 396: 235-42.
  5. Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE, Doroshow JH. Immunohistochemical detection of poly(ADP-ribose)polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Therap 2009; 8: 2004-9.
  6. Jobson AG, Cardellina JH, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R, Pommier Y. Identification of a bis-guanylhydrazone [4,4'-diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Ckh2 kinase. Molec Pharmacol 2007; 7

About the Branch Chief

Dr. Mary K. Wolpert, Ph.D. Dr. Beverly A. Teicher PhD is Chief of the Molecular Pharmaco-logy Branch at NCI, a position that she assumed in early 2011. One focus of the Molecular Pharmacology Branch is target and drug discovery for rare and recalcitrant cancers such as sarcoma and small cell lung cancer. Dr. Teicher completed a PhD in Bioorganic Chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. More…